Breaking News Instant updates and real-time market news.

ABC

AmerisourceBergen

$97.77

8.32 (9.30%)

, WBA

Walgreens Boots Alliance

$68.29

-0.17 (-0.25%)

16:32
02/13/18
02/13
16:32
02/13/18
16:32

On The Fly: Top stock stories for Tuesday

Stocks opened in negative territory and stayed there for most of the morning, though the averages moved into the green to stay by the afternoon. The market's range was significantly tighter than it has been over the past two weeks, though the Dow still managed to trade in a 200-point range. The volume was lighter than it has been, giving further evidence of the extreme volatility slowing down. Oil prices were lower throughout the day but closed little changed ahead of the weekly API inventory report due out after the close. The price of oil is just above $59 a barrel. ECONOMIC EVENTS: There weren't any major U.S. economic reports released. COMPANY NEWS: Shares of AmerisourceBergen (ABC) rose over 9% after The Wall Street Journal reported that Walgreens Boots Alliance (WBA) has made a takeover approach to the drug distributor, in which the pharmacy operator already holds a 26% stake. While the news gave a bump to Amerisource, several of its drug distribution services peers were not being lifted in sympathy. The weight on the sector was likely due to reports that said Amazon (AMZN) is seeking to expand its medical supplies business and that the e-commerce giant's joint venture with Berkshire Hathaway (BRK.A) and JPMorgan (JPM) is aiming to cut out drug distributors such as Amerisource, Cardinal Health (CAH) and McKesson (MCK)... PepsiCo (PEP) shares finished fractionally higher after the company reported better than expected fourth quarter sales and profits. The soda and snack food maker also increased its dividend by 15% and announced a new $15B share repurchase program... Meanwhile, Xerox (XRX) shares slid about 2.5% after the company said that its board reviewed the February 12 letter signed by shareholders Carl Icahn and Darwin Deason, calling the letter "misleading and accurate." Xerox said that the asseration from the two investors that investors are selling control of the company for a cash flow multiple barely exceeding 2.3x is "just plain wrong" and added that following the playbook of Icahn and Deason would be "both highly irresponsible and unlikely to succeed". Xerox also stated that allegations made in a lawsuit filed by Darwin Deason in the Supreme Court of the State of New York "are without merit," adding "the company will vigorously defend itself."... In addition, Walmart (WMT) closed up about 1% after the Wall Street Journal reported that the retail giant is eliminating certain store management positions as it continues its efforts to compete with Amazon in e-commerce. MAJOR MOVERS: Among the notable gainers was Under Armour (UAA), whose Class A shares jumped 17% after the athletic apparel maker reported better than expected fourth quarter sales. Also higher was WMIH Corp. (WMIH), which surged 55% after it entered into a definitive merger agreement with Nationstar Mortgage Holdings (NSM). Additionally, Hardinge (HDNG) gained 7% to $18.35 after it agreed to be acquired by Privet Fund Management for $18.50 per share in cash. Among the noteworthy losers were Patterson Companies (PDCO) and Henry Schein (HSIC), which fell 5% and 6.6%, respectively, after the Federal Trade Commission said it is suing the dental products distributors for conspiring to refuse to provide discounts. INDEXES: The Dow rose 39.18, or 0.16%, to 24,640.45, the Nasdaq gained 31.55, or 0.45%, to 7,013.51, and the S&P 500 advanced 6.94, or 0.26%, to 2,662.94.

ABC

AmerisourceBergen

$97.77

8.32 (9.30%)

WBA

Walgreens Boots Alliance

$68.29

-0.17 (-0.25%)

AMZN

Amazon.com

$1,414.51

28.28 (2.04%)

BRK.A

Berkshire Hathaway

$297,500.00

-1440 (-0.48%)

BRK.B

Berkshire Hathaway

$197.99

-0.9 (-0.45%)

JPM

JPMorgan

$112.43

0.69 (0.62%)

CAH

Cardinal Health

$65.69

-2.34 (-3.44%)

MCK

McKesson

$146.18

-2.84 (-1.91%)

PEP

PepsiCo

$112.14

0.21 (0.19%)

XRX

Xerox

$29.17

-0.78 (-2.60%)

WMT

Walmart

$100.98

1.43 (1.44%)

UAA

Under Armour; also tag UA

$16.70

2.47 (17.36%)

UA

Under Armour; also tag UAA

$15.29

2.11 (16.01%)

WMIH

WMIH

$1.23

0.434 (54.52%)

NSM

Nationstar

$16.63

-0.47 (-2.75%)

HDNG

Hardinge

$18.35

1.27 (7.44%)

PDCO

Patterson Companies

$31.21

-1.71 (-5.19%)

HSIC

Henry Schein

$67.39

-4.79 (-6.64%)

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 16

    Feb

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 18

    Mar

  • 13

    Apr

  • 30

    May

  • 12

    Jun

  • 13

    Jul

  • 12

    Oct

ABC AmerisourceBergen
$97.77

8.32 (9.30%)

02/13/18
WELS
02/13/18
NO CHANGE
WELS
AmerisourceBergen acquisition by Walgreens makes sense, says Wells Fargo
Commenting on The Wall Street Journal report saying Walgreens (WBA) has approached AmerisourceBergen (ABC) in a takeover attempt and the companies remain early in their discussions, Wells Fargo analyst Peter Costa tells investors he believes the acquisition makes sense given the already existing long-term partnership and limited ability to merge laterally. Further, the analyst believes a potential combination could help lower costs and wring out synergies in the U.S. drug distribution channel, and better position Walgreens in the face of increasing competitive threat from a possible Amazon (AMZN) entry. However, a merger might risk alienating AmerisourceBergen's retail pharmacy customers that compete with Walgreens' pharmacies, he contends.
02/13/18
JEFF
02/13/18
NO CHANGE
Target $93
JEFF
Buy
Walgreens deal for AmerisourceBergen would be 'headscratcher,' says Jefferies
Jefferies analyst Brian Tanquilut says that while Walgreens Boots Alliance (WBA) acquiring AmerisourceBergen (ABC) would be accretive to earnings, it would be a "headscratcher" for investors. The companies already have a joint venture that affords both the strategic value that combining would provide, Tanquilut tells investors in a research note after the Wall Street Journal reported that Walgreens approached AmerisourceBergen a few weeks ago. The analyst has a Buy rating on Walgreens with a $93 price target. He adds that the potential deal would allow Walgreens to further expand its U.S. business.
02/13/18
LEER
02/13/18
NO CHANGE
LEER
Walgreens may seek to acquire AmerisourceBergen sooner than expected, says Leerink
Leerink analyst David Larsen notes that The Wall Street Journal reported that Walgreens (WBA) has approached AmerisourceBergen (ABC) about a potential takeover. The analyst is surprised that talks of such a large transaction have surfaced so quickly following the Rite Aid (RAD) deal, but says he has always believed that Walgreens at some point would seek to acquire either Express Scripts (ESRX) or AmerisourceBergen. Given the broad-based speculation in the business press about this deal, it is possible shares of Express Scripts will trade off, Larsen contends.
02/13/18
LOOP
02/13/18
NO CHANGE
Target $90
LOOP
Buy
AmerisourceBergen acquisition by Walgreens would model U.K., says Loop Capital
Loop Capital analyst Andrew Wolf believes that a Walgreens (WBA) and AmerisourceBergen (ABC) full merger would have similar attributes to that of the vertically integrated pharmacy model that Walgreens operates in the U.K. If completed, this transaction would come sooner than the analyst would have anticipated likely spurred by the rapid changes in pharmacy and healthcare occurring around Walgreens. Ultimately, Wolf views this strategic response positively as it would better position a combined company to navigate in the face of industry change and possibly even as a disrupter. He reiterates a Buy rating and $90 price target on Walgreens' shares.
WBA Walgreens Boots Alliance
$68.29

-0.17 (-0.25%)

AMZN Amazon.com
$1,414.51

28.28 (2.04%)

02/13/18
DADA
02/13/18
NO CHANGE
Target $1800
DADA
Buy
Amazon.com investors should take advantage of pullback, says DA Davidson
DA Davidson analyst Tom Forte keeps his Buy rating and $1,800 on Amazon.com but says that investors should take advantage of the latest pullback to add to their positions. In addition to valuation, Forte cites the press reports on the latest hiring of Jennifer Salke as the new head of Amazon Studios, thereby filling "an important void after a potential period of disruption" and bringing one of its most significant areas of investment - proprietary content - back on track. The analyst notes that among Salke's prior accomplishments as the President of NBC Entertainment were hit shows such as "This Is Us", "Glee", "Modern Family", and "Prison Break".
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
02/13/18
MACQ
02/13/18
NO CHANGE
Target $1750
MACQ
Outperform
Amazon's Twitch aggregate viewership continues to rise, says Macquarie
Macquarie analyst Benjamin Schachter says Amazon's (AMZN) Twitch aggregate viewership continues to rise, and Twitch is now bigger than CNN (TWX). While eSports as a whole is becoming a more concrete opportunity, the analyst notes that which games and genres will be the most popular/viewed eSports over time is unclear. Schachter also highlights that the Overwatch League launched to peak views of over 408K and over 10M unique viewers across the opening week, and that display ads on Amazon properties like Twitch are meaningful contributors to Other revenue, which grew 58% to $4.65B in 2017. He reiterates an Outperform rating and $1,750 price target on Amazon's shares.
BRK.A Berkshire Hathaway
$297,500.00

-1440 (-0.48%)

01/31/18
BERN
01/31/18
NO CHANGE
BERN
Bernstein not expecting Amazon/JPMorgan/Berkshire coalition to become insurer
Bernstein analyst Lance Wilkes notes that Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) announced a plan to partner to offer healthcare services to their employees. The analyst does not expect this coalition or new company to become a health insurer, or to create meaningful disruption in core functions of the MCO. Wilkes thinks these three companies will create a new company that will focus on address four high impact areas of healthcare, namely shift to value based care, pharmacy costs, keeping people health/population health management, and consumer engagement. While he believes the retail pharmacy effort of Amazon would not be housed in this coalition, Wilkes argues that this new company may contract with a to-be-developed Amazon online pharmacy.
01/31/18
FBCO
01/31/18
NO CHANGE
FBCO
No impact on pharma/biotech from Amazon/JPM/Berkshire coalition, says Credit Suisse
Commenting on the news that Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) are partnering to offer healthcare services to their employees, Credit Suisse analyst Vamil Divan says he does not anticipate any impact on the pharmaceutical or biotechnology sectors in the near or immediate term. However, he acknowledged that the biopharma pricing and distribution models include some perverse incentives that could be ripe for potential disruption.
01/31/18
CHLM
01/31/18
NO CHANGE
CHLM
Amazon consortium could be longer-term health care disruptor, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich says that Amazon (AMZN), Berkshire Hathaway (BRK.A; BRK.B), and JPMorgan (JPM) new company focused initially on technology solutions to provide simplified, high-quality, and transparent healthcare for their employees and families at a reasonable cost could be a longer-term health care disruptor but it may a little premature to jump to conclusions.
02/05/18
BERN
02/05/18
NO CHANGE
BERN
More pronounced risks to drug supply chain from Amazon coalition, says Bernstein
Bernstein analyst Lance Wilkes thinks the risks to the drug supply chain from Amazon (AMZN), JPMorgan (JPM) and Berkshire Hathaway (BRK.A; BRK.B) healthcare joint venture are much more pronounced than risks to traditional MCOs. The analyst thinks the coalition could acquire a transparency PBM, effectively creating an employer PBM Co-op.
BRK.B Berkshire Hathaway
$197.99

-0.9 (-0.45%)

JPM JPMorgan
$112.43

0.69 (0.62%)

02/05/18
BWSF
02/05/18
NO CHANGE
Target $194
BWSF
Sell
LendingTree lost JPMorgan as mortgage lending customer, says BWS Financial
BWS Financial analyst Hamed Khorsand reports that LendingTree (TREE) has lost JPMorgan Chase (JPM) as a mortgage lending customer, calling it the company's second "high-profile" mortgage lender loss in about a quarter. The loss of JPMorgan matters both because of how many loans it originates but also due to the read-through that the loss has on the concept of LendingTree's calling center adding value for the lender, according to Khorsand, who keeps a Sell rating and $194 price target on LendingTree shares.
02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
KBWI
02/12/18
UPGRADE
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
02/13/18
KBWI
02/13/18
UPGRADE
Target $127
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded JPMorgan to Outperform with an unchanged price target of $127. The analyst views the recent pullback in the shares as a buying opportunity.
CAH Cardinal Health
$65.69

-2.34 (-3.44%)

01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Amazon entry into healthcare markets focused on medical supplies, says Leerink
Leerink analyst David Larsen says that his recent research around Amazon's (AMZN) licensing activity has shown that the company's entry into healthcare markets is, at least for now, focused on medical supplies and devices rather than pharmaceuticals. The analyst believes Owens & Minor (OMI), Cardinal Health (CAH) and Henry Schein (HSIC) are most exposed but that it will take several years for Amazon Business to scale up manufacturer supply relationships to take significant share. Although the top and bottom line impact may be small over the next year or two, Larsen remains cautious on the group as multiples continue to reflect the Amazon threat as well as pricing and volume headwinds.
11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
12/04/17
DBAB
12/04/17
INITIATION
Target $64
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Cardinal Health with a Hold rating and $64 price target. The analyst believes uncertainty around drug pricing and the potential for integration risk with Cordis and the Patient Recovery acquisitions warrant a "more prudent approach" to the shares.
MCK McKesson
$146.18

-2.84 (-1.91%)

01/23/18
NEED
01/23/18
NO CHANGE
Target $180
NEED
Buy
McKesson price target raised to $180 from $173 at Needham
Needham analyst Kevin Caliendo raised his price target on McKesson to $180 and kept his Buy rating ahead of the company's Q3 earnings next week. The analyst expects McKesson to update on the impact of U.S. corporate tax changes on earnings, anticipating it to be a net positive with a forward rate below the currently projected 24% in FY18.
01/24/18
JEFF
01/24/18
UPGRADE
Target $205
JEFF
Buy
McKesson upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded McKesson to Buy and raised his price target for the shares to $205 from $165. The combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels," Tanquilut tells investors in a research note. He sees 20% upside from current share levels.
01/24/18
01/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Buy from Hold at Jefferies analyst Brian Tanquilut saying the combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels." 2. Cree (CREE) upgraded to Hold from Sell at Williams Capital. 3. 3M (MMM) upgraded to Buy from Neutral at Hilliard Lyons with analyst Spencer Joyce saying he sees as a tactical opportunity ahead of its earnings report as he expects estimates to rise following the company's fourth quarter earnings release. 4. Energen (EGN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Calio saying he expects oil markets to tighten and gas to remain weak in 2018. 5. Capital City Bank (CCBG) was upgraded to Outperform from Market Perform at Hovde Group and to Hold from Sell at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
COWN
02/12/18
NO CHANGE
COWN
Recent pullback in drug distributors a buying opportunity, says Cowen
Cowen analyst Charles Ryhee said the recent pullback in drug distributors is unwarranted given the space's improving underlying fundamentals. He said the core distribution business is seeing stable generic pricing for both buy-side and sell-side and he believes concerns regarding likely proposed Medicare Part B changes are overblown. Ryhee reiterated his Outperform rating on both McKesson (MCK) and AmerisourceBergen (ABC) shares.
PEP PepsiCo
$112.14

0.21 (0.19%)

01/29/18
RHCO
01/29/18
INITIATION
Target $125
RHCO
Hold
PepsiCo initiated with a Hold at SunTrust
SunTrust initiated PepsiCo with a Hold and $125 price target.
01/30/18
BERN
01/30/18
NO CHANGE
Target $124
BERN
Market Perform
Dr Pepper Snapple price target raised to $124 from $92 at Bernstein
Bernstein analyst Ali Dibadj raised his price target for Dr Pepper Snapple to $124 from $92 after the company and Keurig Green Mountain announced a definitive merger agreement to create public company Keurig Dr Pepper. While the analyst views this merger as good for Dr Pepper Snapple shareholders, there are unanswered questions about the prospects as a combined entity, with revenue synergies remaining unclear, synergy targets appearing stretched, and the Coca-Cola (KO)/PepsiCo (PEP) distribution partnership remaining a risk. Dibadj reiterates a Market Perform rating on Dr Pepper Snapple's shares.
01/29/18
01/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PepsiCo (PEP) initiated with a Hold at SunTrust. 2. Synlogic (SYBX) initiated with an Overweight at Piper Jaffray. 3. Centennial Resource Development (CDEV) initiated with a Buy at Guggenheim. 4. Zynerba (ZYNE) initiated with a Buy at Ladenburg. 5. Radius Health (RDUS) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
RHCO
01/29/18
INITIATION
Target $125
RHCO
Hold
PepsiCo initiated with a Hold at SunTrust
As reported earlier, SunTrust analyst William Chappell initiated PepsiCo (PEP) with a Hold rating and a price target of $125. Chappell contends that after 5 years of price and promotion with Coca-Cola (KO), the companies' next phase will likely see "price increases or at least less promotional activity" on some beverage items. The analyst also notes that the investor concerns about the snacking category are overblown, pointing some recovery in Q4, while the positive FX, emerging markets, and tax reform dynamics create more tailwinds.
XRX Xerox
$29.17

-0.78 (-2.60%)

02/05/18
UBSW
02/05/18
UPGRADE
Target $38
UBSW
Buy
Xerox upgraded to Buy from Neutral at UBS
UBS analyst Steven Milunovich upgraded Xerox to Buy and raised his price target for the shares to $38 from $34.50. The analyst is positive on "deal optionality" from the Fuji Xerox merger and notes the company's fundamentals are improved following the Q4 results. The market is underappreciating "upside optionality" from Fuji Xerox deal, according to which shareholders would receive $9.80 per share in cash and 50% of the new Fuji Xerox, Milunovich tells investors in a research note. His post-deal theoretical valuation for Xerox is $40 per share.
12/07/17
LOOP
12/07/17
NO CHANGE
Target $38
LOOP
Buy
Xerox offers positive near-term outlook and cost savings, says Loop Capital
Loop Capital analyst Ananda Baruah kept his Buy rating and $38 price target after meeting with management of Xerox yesterday. Baruah says the company continues to offer compelling near-term catalysts, namely a "reasonable December quarter guidance", 4-8 quarter setup with savings not accounted for by consensus, and incremental revenue growth initiatives. The analyst says the stock is valued attractively and should have traded up 5% rather than down 15% after the September quarter results, since it exceeded the Street operations metrics views excluding one-time items.
01/31/18
STPT
01/31/18
DOWNGRADE
STPT
Hold
Xerox downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Xerox to Hold, citing the company's deal to merge with the Fuji Xerox joint venture.
02/12/18
UBSW
02/12/18
NO CHANGE
Target $38
UBSW
Buy
UBS confident in potential deal between Xerox and Fujifilm
UBS analyst Steven Milunovich met with Xerox (XRX) management to discuss its potential deal with Fujifilm (FUJIY) and came away confident both were on the same page, that Jacobson is a good CEO choice to implement tough decisions, and that synergies will be achievable. Milunovich has a Buy rating and $38 price target on Xerox shares.
WMT Walmart
$100.98

1.43 (1.44%)

01/26/18
LEHM
01/26/18
NO CHANGE
Target $120
LEHM
Overweight
Walmart price target raised to $120 from $110 at Barclays
Barclays analyst Karen Short raised her price target for Walmart to $120 despite lowering her earnings estimates for the retailer. Short dropped her fiscal 2019 earnings per share estimate to $5.20 from $5.40 to reflect the increase in U.S. starting wages, the closure of certain Sam's Club stores and "increased visibility" into the U.S. tax rate. The analyst notes, however, that she didn't raise her price target for Walmart shares when increasing estimates for the entire sector due to tax reform. Short keeps an Overweight rating on Walmart.
02/08/18
SBSH
02/08/18
NO CHANGE
Target $117
SBSH
Buy
Citi views upcoming Q4 earnings report from Walmart as catalyst
Citi analyst Kate McShane thinks Walmart's Q4 earnings report on February 20 will be a catalyst for the shares. Given positive holiday commentary from several retailers, the potential upside risk to comps is high, McShane tells investors in a pre-earnings research note. Her same-store-sales assumption for Q4 is up 3.0%, which is higher than the Street's up 2.0%. Should same-store-sales come in better than 3%, the stock will likely see "notable upside," McShane contends. The analyst keeps a Buy rating on Walmart with a $117 price target.
01/18/18
01/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Matthew Fassler saying selling consumables to middle-income consumers in small markets remains a compelling strategic position. 2. Hertz (HTZ) upgraded to Outperform from Neutral at Macquarie with analyst Hamzah Mazari saying he is more bullish on 2018 rental car pricing given fleet cutting by Enterprise, the positive impact on corporate travel from tax reform, and the potential US infrastructure bill creating excess demand. For Hertz specifically. 3. Alarm.com (ALRM) upgraded to Buy from Hold at Jefferies analyst John DiFucci saying Alarm.com is at the forefront of the trend towards connected homes and devices. 4. PPL Corp. (PPL) upgraded to Buy from Hold at Deutsche Bank with analyst Jonathan Arnold saying the current valuation is "too cheap to ignore," and U.K. energy regulator Ofgem failing to implement a mid-period review of RIIO-ED1 offers "decent prospects for a near-term re-rating catalyst." 5. Fluor (FLR) upgraded to Outperform from Neutral at Credit Suisse with analyst Jamie Cook saying investors will gravitate back to Engineering & Construction stocks as fundamentals for the group are improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/18
MSCO
01/25/18
NO CHANGE
Target $74
MSCO
Equal Weight
Tractor Supply worries about Amazon risk overblown, for now, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said his survey of 800 consumers living within 20 miles of a Tractor Supply (TSCO) store suggests there is no cause for immediate concern about the e-commerce threat in pet food, but there are "warning signs that bear watching." Chewy.com, Walmart.com (WMT) and Amazon (AMZN) are gaining significant traction online in pet food and the evolution of shopping patterns could pose a long-term risk to Tractor Supply, though the e-commerce risk does not appear imminent, said Gutman, who keeps an Equal Weight rating on Tractor Supply shares.
UAA Under Armour; also tag UA
$16.70

2.47 (17.36%)

02/13/18
JEFF
02/13/18
NO CHANGE
Target $24
JEFF
Buy
Jefferies says buy Under Armour after quarter shows brand is strong
Jefferies analyst Randal Konik says this morning's sales beat and strength in direct-to-consumer as well as international prove the brand is "strong globally." Wholesale was muted but not unexpected given the environment, Konik tells investors in a post-earnings research note. The analyst believes this quarter will mark a trough in the earnings revision cycle. He sees better sales, margins, and earnings in the coming quarters and recommends buying the stock. Konik keeps a Buy rating on Under Armour with a $24 price target.
02/09/18
JEFF
02/09/18
NO CHANGE
JEFF
Buy
Under Armour discounting down dramatically in last three months, says Jefferies
Jefferies analyst Randal Konik says his firms' February webscrapes point to better traction at Under Armour (UAA) with discounts down in each of the last three months. The company's discounts decreased from 70% in November to 23% in February, down more than 30% year-over-year this month, Konik tells investors in a research note. Further, a survey of 200 footwear retailers shows the Under Armour HOVR Phantom is building momentum, the analyst adds. In addition, the survey shows Nike (NKE) is gaining back share from adidas (ADDYY) in running across the U.S. and Europe. In Basketball, Nike continues to dominate, while Under Armour's Curry 4 is resonating well with consumers, Konik writes. The analyst has a Buy rating on Under Armour and Hold rating on Nike.
02/06/18
JEFF
02/06/18
NO CHANGE
Target $72
JEFF
Hold
Jefferies sees too much management turnover at lululemon
The level of management turnover at lululemon during "this critical juncture in the company's growth trajectory gives us some pause," Jefferies analyst Randal Konik tells investors in a research note following the resignation of CEO Laurent Potdevin. The analyst sees better opportunities elsewhere, namely in shares of Under Armour (UAA), given lululemon's "high" valuation high and "less plentiful" margin opportunity going forward. He maintains a Hold rating on lululemon with a $72 price target.
02/13/18
BARD
02/13/18
NO CHANGE
Target $22
BARD
Outperform
Under Armour price target raised to $22 from $17 at Baird
UA Under Armour; also tag UAA
$15.29

2.11 (16.01%)

01/16/18
01/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Neutral at Macquarie with analyst Laurent Vasilescu citing weaker North America revenues, flat Connected Fitness revenues, international revenues of up 21% year-over-year, gross margin pressure, and higher SG&A assumptions. 2. Verizon (VZ) downgraded to Neutral from Buy at MoffettNathanson. 3. Lockheed Martin (LMT) and Rockwell Collins (COL) were downgraded to Market Perform from Outperform at Wells Fargo. 4. Spirit Airlines (SAVE) downgraded to Hold from Buy at Stifel with analyst Joseph DeNardi saying he believes Spirit will benefit this year from an improving demand and revenue environment, but that its higher revenue risk relative to potential competitive responses to its expected capacity growth is not fully reflected in the stock at current levels. 5. Finisar (FNSR) downgraded to Sell from Neutral at Goldman Sachs with analyst Doug Clark saying risks of oversupply and competition are heating up in the optical component landscape. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WMIH WMIH
$1.23

0.434 (54.52%)

02/13/18
02/13/18
DOWNGRADE
Target $13.5

Underweight
Nationstar downgraded to Underweight on dilutive WMIH deal at Piper Jaffray
As previously reported, Piper Jaffray analyst Kevin Barker downgraded Nationstar (NSM) to Underweight from Neutral, as he believes the dilution to existing shareholders from the company's deal with WMIH Corp. (WMIH) will ultimately reduce the economic value of pro forma tangible book value by about $3 per share. Additionally, the incremental cost of adding debt will further reduce pretax earnings, said Barker, who lowered his price target on Nationstar shares to $13.50 from $18.
NSM Nationstar
$16.63

-0.47 (-2.75%)

02/13/18
PIPR
02/13/18
DOWNGRADE
PIPR
Underweight
Nationstar downgraded to Underweight from Neutral at Piper Jaffray
11/21/17
PIPR
11/21/17
UPGRADE
Target $16.5
PIPR
Neutral
Nationstar upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst Kevin Barker upgraded Nationstar Mortgage Holdings to Neutral saying the shares are now fairly priced near tangible book value. Further, the analyst believes Nationstar could be worth $15-$21 per share in a takeout scenario. He upped his price target for the stock to $16.50 from $15.50.
04/04/17
COMP
04/04/17
UPGRADE
COMP
Neutral
Nationstar upgraded to Neutral from Sell at Compass Point
HDNG Hardinge
$18.35

1.27 (7.44%)

PDCO Patterson Companies
$31.21

-1.71 (-5.19%)

02/13/18
WBLR
02/13/18
NO CHANGE
WBLR
William Blair sees FTC suit pressuring Henry Schein, Patterson shares
The Federal Trade Commission yesterday announced it was filing an antitrust suit against Henry Schein (HSIC), Patterson Companies (PDCO), and Benco, the three largest dental distributors in the United States, William Blair analyst John Kreger tells investors in a research note. The analyst says that while this is not the first time anti-competitive allegations have been made against the companies, the FTC complaint will likely "add credence to the antitrust argument, increase the visibility of the risk, and exacerbate investor concerns about the sustainability of pricing and margins." Kreger believes this could put further pressure on the valuations of Henry Schein and Patterson in the near term, particularly until there is some clear evidence of a spending rebound in dental. He has an Outperform rating on Henry Schein and Market Perform rating on Patterson.
02/13/18
LEER
02/13/18
NO CHANGE
LEER
Market Perform
FTC suit could result in longer-term margin headwinds for Henry Schein, says Leerink
Leerink analyst David Larsen notes that the FTC announced a lawsuit against Henry Schein (HSIC), Patterson (PDCO), and Benco for antitrust pricing behavior. The analyst views this news as being "very serious," and could result in longer-term margin headwinds and multiple compression for Henry Schein. He reiterates a Market Perform on Henry Schein's shares.
01/04/18
EVER
01/04/18
INITIATION
Target $38.5
EVER
In Line
Patterson Companies initiated with an In Line at Evercore ISI
Evercore ISI started Patterson Companies with an In Line rating and $38.50 price target.
12/20/17
NRCS
12/20/17
NO CHANGE
Target $53
NRCS
Buy
Patterson didn't really lose biggest veterinary customer, says Northcoast
Northcoast analyst Ed Snyder notes that competitor sell-side reports have suggested that Patterson Companies lost its biggest veterinary customer, The Veterinary Cooperative, which will now be serviced primarily by MWI Veterinary. However, TVC is a cooperative that negotiates price discounts and does not take inventory, meaning it is not a customer, explains Snyder. Rather than continuing to give TVC an additional price discount, Patterson is choosing to reinvest those dollars in its own loyalty program, said Snyder, who contends that competitor research "misrepresent the facts and therefore overstate the risk." He maintains a Buy rating and $53 price target on Patterson shares.
HSIC Henry Schein
$67.39

-4.79 (-6.64%)

01/04/18
EVER
01/04/18
INITIATION
Target $81
EVER
Outperform
Henry Schein initiated with an Outperform at Evercore ISI
Evercore ISI started Henry Schein with an Outperform rating and $81 price target.
12/27/17
PIPR
12/27/17
NO CHANGE
Target $78
PIPR
Overweight
Piper sees Henry Schein positioned well against Amazon in Florida
After visiting one of Henry Schein's (HSIC) top five consumable distribution centers, in Jacksonville, Florida, a market where Amazon (AMZN) has recently made investments, Piper Jaffray analyst Sarah James says the company's offerings may stack up well to Amazon. She highlights Henry Schein's ability to distribute 94% of orders next day with a 99% accuracy rate. The analyst believes the company's customer retention could be higher than the market expects driven by partnerships with dentists to manage inventory and maximize revenue generating space. Henry Schein's main defense against Amazon is customer service and the "sticky behavior" of doctors/dentists, James tells investors in a research note titled "Learning from Ground Zero of the War on Amazon and Dental Consumable Trends." She keeps an Overweight rating on Henry Schein with a $78 price target.

TODAY'S FREE FLY STORIES

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:26
02/24/18
02/24
16:26
02/24/18
16:26
Hot Stocks
Buffett believes Berkshire can handle $400B mega-catastrophe »

In his annual letter to…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:19
02/24/18
02/24
16:19
02/24/18
16:19
Periodicals
Buffet says laments inability to find targets for Berkshire to buy, Reuters says »

Warren Buffett lamented…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:16
02/24/18
02/24
16:16
02/24/18
16:16
Periodicals
Berkshire Hathaway reports record profit fueled by tax reform, Reuters says »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.66

0.55 (1.71%)

16:12
02/24/18
02/24
16:12
02/24/18
16:12
Periodicals
Twitter's SoundCloud investment officially wiped out, Recode reports »

Twitter has written off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

AAPL

Apple

$175.50

3 (1.74%)

16:08
02/24/18
02/24
16:08
02/24/18
16:08
Periodicals
Apple to store sensitive encryption keys in China, WSJ reports »

Apple will start to store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

16:00
02/24/18
02/24
16:00
02/24/18
16:00
Periodicals
Volkswagen's U.S. unit settles emissions suit, Reuters reports »

Volkswagen's unit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

, UAL

United Continental

$67.57

0.87 (1.30%)

15:56
02/24/18
02/24
15:56
02/24/18
15:56
Periodicals
Delta, United Airlines cut ties with NRA, Reuters reports »

Delta Air Lines (DAL) and…

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

UAL

United Continental

$67.57

0.87 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 30

    May

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

15:53
02/24/18
02/24
15:53
02/24/18
15:53
Earnings
Berkshire Hathaway reports Q4 operating EPS $3,338, consensus $2,622.23 »

Reports FY17 operating…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.70

0.33 (0.35%)

, T

AT&T

$36.72

0.25 (0.69%)

15:44
02/24/18
02/24
15:44
02/24/18
15:44
Periodicals
May be time to consider Time Warner, Barron's says »

Time Warner (TWX) shares…

TWX

Time Warner

$94.70

0.33 (0.35%)

T

AT&T

$36.72

0.25 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 23

    Apr

JKHY

Jack Henry

$121.95

1.79 (1.49%)

12:59
02/24/18
02/24
12:59
02/24/18
12:59
Conference/Events
Jack Henry management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

PFBC

Preferred Bank

$64.05

0.86 (1.36%)

12:52
02/24/18
02/24
12:52
02/24/18
12:52
Conference/Events
Preferred Bank management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 24

    Sep

R

Ryder

$74.54

0.19 (0.26%)

12:47
02/24/18
02/24
12:47
02/24/18
12:47
Conference/Events
Ryder management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ASPU

Aspen Group

$8.85

1.48 (20.08%)

12:29
02/24/18
02/24
12:29
02/24/18
12:29
Conference/Events
Aspen Group to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

TWTR

Twitter

$32.66

0.55 (1.71%)

, AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

10:47
02/24/18
02/24
10:47
02/24/18
10:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWTR

Twitter

$32.66

0.55 (1.71%)

AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

RGR

Sturm, Ruger

$49.90

0.9 (1.84%)

X

U.S. Steel

$43.52

0.54 (1.26%)

STLD

Steel Dynamics

$47.47

-0.53 (-1.10%)

NUE

Nucor

$66.94

-0.01 (-0.01%)

AKS

AK Steel

$5.50

-0.12 (-2.14%)

AET

Aetna

$175.55

0.49 (0.28%)

ANTM

Anthem

$235.24

1.56 (0.67%)

CNC

Centene

$100.45

0.96 (0.96%)

CI

Cigna

$194.79

2.89 (1.51%)

HNT

Health Net

HUM

Humana

$271.19

3.38 (1.26%)

MOH

Molina Healthcare

$72.94

1.38 (1.93%)

UNH

UnitedHealth

$230.16

3.07 (1.35%)

WCG

WellCare

$192.05

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 16

    Apr

  • 30

    May

DBX

Dropbox

, SNAP

Snap

$17.45

-0.06 (-0.34%)

09:49
02/24/18
02/24
09:49
02/24/18
09:49
Periodicals
Dropbox IPO bodes well, Barron's says »

In a follow-up article…

DBX

Dropbox

SNAP

Snap

$17.45

-0.06 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

IPG

Interpublic Group

$24.24

0.3 (1.25%)

, OMC

Omnicom

$77.31

0.52 (0.68%)

09:42
02/24/18
02/24
09:42
02/24/18
09:42
Periodicals
Advertising companies cheaper than usual, Barron's says »

After a tumble last year,…

IPG

Interpublic Group

$24.24

0.3 (1.25%)

OMC

Omnicom

$77.31

0.52 (0.68%)

PUBGY

Publicis

$18.82

0.09 (0.48%)

WPP

WPP

$95.30

0.93 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

MSFT

Microsoft

$94.06

2.33 (2.54%)

, INTC

Intel

$47.73

1.93 (4.21%)

09:36
02/24/18
02/24
09:36
02/24/18
09:36
Periodicals
Quantum computing soon to be reality, Barron's says »

Microsoft (MSFT) predicts…

MSFT

Microsoft

$94.06

2.33 (2.54%)

INTC

Intel

$47.73

1.93 (4.21%)

NVDA

Nvidia

$245.93

3.78 (1.56%)

MU

Micron

$46.53

2.28 (5.15%)

GOOG

Alphabet

$1,126.79

20.16 (1.82%)

GOOGL

Alphabet Class A

$1,128.09

18.19 (1.64%)

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

09:26
02/24/18
02/24
09:26
02/24/18
09:26
Periodicals
Many downsides when Amazon's HQ2 comes to town, Barron's says »

As Amazon decides on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.